Rituximab or Rituximab biosimilar

DRUG3 trials

Sponsors

University of Pennsylvania, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., University of Utah

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)GlioblastomaPost-transplant Lymphoproliferative Disorder

Phase 1

CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy

RecruitingNCT06973096

University of PennsylvaniaGlioblastoma

Start: 2025-07-18End: 2042-07-01Target: 9Updated: 2026-05-11

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

RecruitingNCT07124936

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Diffuse Large B Cell Lymphoma (DLBCL)

Start: 2025-07-30End: 2029-10-25Target: 97Updated: 2025-08-15

Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)

Not yet recruitingNCT07573436

University of UtahPost-transplant Lymphoproliferative Disorder

Start: 2026-06-01End: 2031-06-01Target: 23Updated: 2026-05-07